Rindopepimut with Temodar Appears Promising in Newly Diagnosed Glioblastoma Multiforme (06/14/2010)
Maintenance therapy with rindopepimut (CDX-110) combined with Temodar® (temozolomide) resulted in a 70% progression-free rate at 5.5 months for newly diagnosed patients with glioblastoma multiforme (GBM). These findings were recently presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

Recurrent High-grade Glioma Patients May Benefit from Hypofractionated Stereotactic Radiation Therapy (06/01/2010)
Patients with recurrent, high-grade glioma who were treated with hypofractionated stereotactic radiation therapy (H-SRT) experienced minimal side effects and a median survival of 11 months. These results were recently published in the Journal of Clinical Oncology.

Ted Kennedy’s Recent Diagnosis of Glioblastoma Raises Awareness of Brain Cancer (05/24/2010)
The recent diagnosis of Ted Kennedy with brain cancer has raised awareness of this disease which affects approximately 20,000 people in the United States each year, but individuals should be encouraged as they fight this illness; the treatment options available today are providing more hope than ever before.

Link Between Cell Phone Use and Brain Tumors Remains Inconclusive (05/19/2010)
A large, international study has found no conclusive evidence that cell phone use increases the risk for brain tumors, according to an early online publication in the International Journal of Epidemiology.

Continuous Temodar Shows Promise Against Recurrent Glioma (04/01/2010)
Among patients with recurrent malignant glioma, treatment with continuous dose-intense Temodar® (temozolomide) shows promising safety and efficacy. The results of this Phase II clinical trial were published in the Journal of Clinical Oncology.

▪ More...

Rindopepimut with Temodar Appears Promising in Newly Diagnosed Glioblastoma Multiforme (06/14/2010)
Maintenance therapy with rindopepimut (CDX-110) combined with Temodar® (temozolomide) resulted in a 70% progression-free rate at 5.5 months for newly diagnosed patients with glioblastoma multiforme (GBM). These findings were recently presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

Recurrent High-grade Glioma Patients May Benefit from Hypofractionated Stereotactic Radiation Therapy (06/01/2010)
Patients with recurrent, high-grade glioma who were treated with hypofractionated stereotactic radiation therapy (H-SRT) experienced minimal side effects and a median survival of 11 months. These results were recently published in the Journal of Clinical Oncology.

Ted Kennedy’s Recent Diagnosis of Glioblastoma Raises Awareness of Brain Cancer (05/24/2010)
The recent diagnosis of Ted Kennedy with brain cancer has raised awareness of this disease which affects approximately 20,000 people in the United States each year, but individuals should be encouraged as they fight this illness; the treatment options available today are providing more hope than ever before.

Link Between Cell Phone Use and Brain Tumors Remains Inconclusive (05/19/2010)
A large, international study has found no conclusive evidence that cell phone use increases the risk for brain tumors, according to an early online publication in the International Journal of Epidemiology.

Continuous Temodar Shows Promise Against Recurrent Glioma (04/01/2010)
Among patients with recurrent malignant glioma, treatment with continuous dose-intense Temodar® (temozolomide) shows promising safety and efficacy. The results of this Phase II clinical trial were published in the Journal of Clinical Oncology.

▪ More...